Nick Shaxson ■ Pfizer: tax dodger, price gouger
A new report from Americans for Tax Fairness concludes:
“In addition to dodging its fair share of taxes, Pfizer—maker of Celebrex, Lipitor, Lyrica, and Viagra, among many other health-care products—has also been aggressively raising prescription drug prices, thereby straining patients and our health care system and in some cases putting needed medications out of reach.
By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once. In the company’s biggest insult to America yet, Pfizer’s merger will allow it to go on enjoying all the benefits of being based here—everything from a publicly educated workforce to an excellent communications infrastructure to a reliable patent system—without adequately paying to support them.”
The two wealth-extracting techniques go together, very often. This is what modern capitalism is increasingly becoming.
Why doesn’t Pfizer’s leadership focus on what it was originally set up to do: wealth creation? And don’t get us started on shareholder value.
The author
Related articles
Let’s make Elon Musk the world’s richest man this Christmas!
The best of times, the worst of times (please give generously!)
Admin Data for Tax Justice: A New Global Initiative Advancing the Use of Administrative Data for Tax Research
2025: The year tax justice became part of the world’s problem-solving infrastructure
Bled dry: The gendered impact of tax abuse, illicit financial flows and debt in Africa
Bled Dry: How tax abuse, illicit financial flows and debt affect women and girls in Africa
9 December 2025
Indicator deep dive: ‘patent box regimes’
Two negotiations, one crisis: COP30 and the UN tax convention must finally speak to each other
‘Illicit financial flows as a definition is the elephant in the room’ — India at the UN tax negotiations
